Ionis Pharmaceuticals is a biotechnology company focused on discovering and developing RNA-targeted therapies for various diseases. Its core products include antisense oligonucleotides, which are designed to treat conditions such as neurological disorders and cardiovascular diseases. Major business segments encompass research and development, collaborations with pharmaceutical companies, and product commercialization. The primary revenue sources are collaborations and licensing agreements with larger pharmaceutical firms, as well as potential future product sales.
The investment profile of Ionis Pharmaceuticals is more aligned with growth investors due to its focus on innovative therapies and potential for future revenue from product commercialization. However, the high risk associated with its current financial performance and market volatility may deter conservative investors. The stock may appeal to those willing to accept higher risk for the possibility of significant returns over time.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-09 | — | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-10-21 | BMO Capital | Update | — → 66 | 44.27 |
| 2026-10-20 | Raymond James | Target Lowered | 84 → 79 | 44.6707 |
| 2026-10-15 | UBS | Rating Upgraded | — → 88 | 42.7 |
| 2026-09-24 | Oppenheimer | Update | — → 85 | 43.93 |
| 2026-09-15 | Guggenheim | Target Lowered | — → 80 | 51.44 |
| 2026-09-09 | Barclays | Target Lowered | 90 → 85 | 56.71 |
| 2026-09-08 | Raymond James | Target Lowered | 87 → 84 | 56.4202 |
| 2026-09-08 | Morgan Stanley | Target Lowered | 110 → 104 | 56.695 |
| 2026-09-08 | Canaccord Genuity | Target Lowered | 95 → 85 | 58.09 |
| 2026-09-08 | BMO Capital | Target Lowered | 61 → 54 | 58.09 |
| 2026-09-08 | Goldman Sachs | Target Lowered | 69 → 56 | 58.09 |
| 2026-09-04 | BMO Capital | Target Raised | 60 → 61 | 58.13 |
| 2026-07-30 | H.C. Wainwright | Target Lowered | — → 115 | 54.04 |
| 2026-07-29 | Goldman Sachs | Target Raised | 66 → 69 | 54.04 |
| 2026-07-21 | Guggenheim | Target Lowered | — → 89 | 52.95 |
| 2026-07-13 | RBC Capital | Target Lowered | 100 → 85 | 56.925 |
